Oncology News | pharmaphorum

News

Nerve damage-tracking pen to be used in CAR-T patients

Nerve damage is a recognised side effect of some CAR-T therapies for cancer, and one that could be spotted early using a pen device developed by UK company Manus Neurodyna

News

J&J claims first approval for PARP combo Akeega

Johnson & Johnson has picked up its first regulatory approval worldwide for Akeega, a fixed-dose combination of a PARP inhibitor and anti-androgen therapy, as a treatm

News

BMS goes down the Tubulis route for cancer ADCs

Bristol-Myers Squibb has formed another alliance focusing on antibody-drug conjugates (ADCs) for solid tumours, paying German biotech Tubulis $22.75 million upfront to get

News

Roche’s Polivy gets FDA OK in frontline lymphoma

The FDA has set aside reservations it had about the use of Roche’s Polivy as a first-line treatment with chemotherapy for diffuse large B-cell lymphoma (DLBCL), and cleare

News

Leaked data shows stellar efficacy for J&J’s Carvykti

Johnson & Johnson was preparing to divulge the data from its eagerly-awaited CARTITUDE-4 trial of CAR-T therapy Carvykti later this year, but a leak of the data has gi

News

Cancer vaccines come to the fore at AACR

This year’s American Association of Cancer Research (AACR) annual meeting saw a clutch of new studies on therapeutic vaccines that suggest the approach is starting to gain

Nerve damage-tracking pen to be used in CAR-T patients

J&J claims first approval for PARP combo Akeega

BMS goes down the Tubulis route for cancer ADCs

Roche’s Polivy gets FDA OK in frontline lymphoma

Leaked data shows stellar efficacy for J&J’s Carvykti

Cancer vaccines come to the fore at AACR

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks